Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica
Mônica Mendes Kangussu-Marcolino, Upinder Singh
Abstract
], 0.39) as the most potent; and (ii) mTOR or phosphatidylinositol 3-kinase (PI3K) inhibitors, with 8 compounds in clinical development, of which 4 have nanomolar potency. Overall, these are promising candidates and represent a significant advance for development of drugs against E. histolytica.
Topics & Concepts
Entamoeba histolyticaParomomycinRepurposingMetronidazoleDysenteryPI3K/AKT/mTOR pathwayDrug repositioningBiologyEntamoebaMedicineMicrobiologyPharmacologyAntibioticsAminoglycosideGeneticsDrugEcologyApoptosisAmoebic Infections and TreatmentsDiagnosis and treatment of tuberculosisPancreatic and Hepatic Oncology Research